Patent classifications
A23V2400/113
PROBIOTIC BEVERAGES CONTAINING A CANNABINOID
Disclosed herein are probiotic beverages containing cannabinoid. The beverages disclosed herein may be formulated as water-based drinks or yogurt drinks, for example, and contain live, active cultures of probiotic microorganisms or may contain spores of probiotic microorganisms. The beverages may additionally include prebiotic substances to enhance the growth and colonization of the probiotic microorganisms in the intestines. The beverages have anti-inflammatory effects due to the presence of the cannabinoid but are non-narcotic. Further, the beverages serve to enhance gut health due to the presence of probiotics and optional prebiotics. The beverages are, at a minimum, composed of water, a cannabinoid, a probiotic microorganism, and optionally a tea extract, but may contain other components such as prebiotics, vitamins, minerals, other nutrients, and other natural products to provide additional health benefits and/or to improve the flavor, texture, and aroma of the beverages.
STABLE DRY PROBIOTIC COMPOSITIONS FOR SPECIAL DIETARY USES
A dry stable probiotic composition is provided. The composition comprises one or more viable probiotic microorganisms, one or more hydrolyzed proteins, one or more disaccharides, one or more oligosaccharides, and one or more polysaccharides, but not trehalose. The composition has viability of at least 1×10.sup.10 CFU/g, and a viability loss of less than 1 log unit/g after one month at a temperature of 40° C. and a relative humidity of 33%. Also provided are methods for preparing the dry stable probiotic composition.
Pharmaceutical composition and food composition with strains of lactic acid bacteria for improving of kidney disease and inhibiting inflammation
The present invention provides a lactobacillus strain-containing pharmaceutical composition and food composition for improving of kidney disease and inhibiting inflammation, which comprises an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including BLI-02 strain, CGMCC No. 15212, Bifidobacterium longum subsp. infantis, TYCA06 strain, CGMCC No. 15210, Lactobacillus acidophilus, VDD088 strain, CGMCC No. 15211, Bifidobacterium bifidum, and combinations thereof.
MICROBIAL FERMENTATION COMPOSITION AND USE THEREOF
A microbial fermentation composition is prepared through after extracting and enzymolyzing selected Edible and medicinal fungi Agaricus blazei, Lentinus edodes, Flammulina velutipes and ginseng of reinforcing vital energy, adding trace elements selenium, zinc and molybdenum, and fermenting and transforming by probiotics. It is demonstrated through experiments of in vitro inhibition of HepGII cells (a liver cancer cell) and Hela cells (a cervical cancer cell) that the fermentation composition formed by probiotic fermentation has significant inhibitory effect on the proliferation of tumor cells. Compared with the non-fermented composition, the fermentation composition has a significantly enhanced inhibitory effect on experimental tumor cells and the difference is significant. The inhibitory effect of the fermentation composition on experimental tumor cells increases with the increase of the concentration.
GOS PRE-CONDITIONING L. REUTERI AND GOS IN FINAL FORMULATION
The invention herein relates generally to enhancing the survival and activity of probiotic Lactobacillus reuteri strains in mammals by pre-conditioning L. reuteri with GOS during cultivation and to a surprisingly high symbiotic effect of such a pre-conditioned probiotic L. reuteri strain when administered together with GOS further added in the composition. The invention therefore comprises methods for cultivating and manufacturing probiotic L. reuteri strains, and preparing products containing such pre-conditioned strains in combination with additional amounts of GOS. In more detail the present invention relates to a probiotic composition comprising a probiotic L. reuteri strain, obtained by a step of growing the bacteria in a medium comprising GOS, and administering the pre-conditioned bacteria together with further GOS in the final product. The inventors have found that such method induces surprisingly high and unexpected symbiotic beneficial effects of the probiotic bacteria in the gastrointestinal tract. The probiotic composition also induces an increased calcium and iron solubility.
FERMENTED MILK FOR REGULATING GUT HEALTH AND PREPARATION METHOD THEREOF
Raw materials of a fermented milk include partially degreased raw milk, 4-10% w/w of saccharide based on the mass of the raw milk, 0.06-0.15% w/w of lactase based on the mass of the raw milk, 0.03-0.18% w/w of a stabilizer based on the mass of the raw milk, and 20-50 dcu of fermenting bacteria added per 100 kg of the raw milk; and the fermenting bacteria is one or more selected from the group consisting of Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus acidophilus, Bifidobacterium lactis and Streptococcus thermophilus, and preferably one or more selected from the group consisting of Lactobacillus plantarum with a preservation number of CGMCC No. 19748, Lactobacillus acidophilus with a preservation number of CGMCC No. 1084 and Streptococcus thermophilus. According to the fermented milk and a preparation method thereof, the prepared fermented milk has a more stable state during the shelf life.
Stable dry probiotic compositions for special dietary uses
A dry stable probiotic composition is provided. The composition comprises one or more viable probiotic microorganisms, one or more hydrolyzed proteins, one or more disaccharides, one or more oligosaccharides, and one or more polysaccharides, but not trehalose. The composition has viability of at least 110.sup.10 CFU/g, and a viability loss of less than 1 log unit/g after 3 months at a temperature of 40 C. and a relative humidity of 33%. Also provided are methods for preparing the dry stable probiotic composition.
Methods for maintaining and improving kidney function in patients with kidney disease and on standard of care therapy
Method for maintaining and improving reduced kidney function and improving quality of life in patients suffering from diseases that result in reduced renal function comprising administering RENDAYL in combination with standard of care treatment.
PROBIOTICS AND FERMENTATION METABOLITES FOR THE PREVENTION AND TREATMENT OF DISEASE CONDITIONS IN ANIMALS
The present invention is directed to compositions comprising a mixture of microbes and the metabolites produced when the microbes are grown together. The invention is further directed to methods for making and using the compositions.
PROBIOTICS AND FERMENTATION METABOLITES FOR THE PREVENTION AND TREATMENT OF DISEASE CONDITIONS IN ANIMALS
The present invention is directed to compositions comprising a mixture of microbes and the metabolites produced when the microbes are grown together. The invention is further directed to methods for making and using the compositions.